We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+8.76%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$13.8B
AUM Growth
-$581M
(-4%)
Cap. Flow
-$2.79B
Cap. Flow
% of AUM
-20.16%
Top 10 Holdings %
Top 10 Hldgs %
25.18%
Holding
905
New
29
Increased
148
Reduced
448
Closed
194
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$66.4M |
| 2 |
Valero Energy
VLO
|
+$28.9M |
| 3 |
SLB Ltd
SLB
|
+$24.8M |
| 4 |
BNY
Bank of New York Mellon
BNY
|
+$22.6M |
| 5 |
PepsiCo
PEP
|
+$20.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$182M |
| 2 |
Apple
AAPL
|
+$148M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$90.9M |
| 4 |
Amgen
AMGN
|
+$72.1M |
| 5 |
Tesla
TSLA
|
+$66.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.26% |
| 2 | Technology | 28.78% |
| 3 | Financials | 8.15% |
| 4 | Consumer Discretionary | 7.54% |
| 5 | Industrials | 7.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BLD
151
DELISTED
TopBuild
BLD
| $21.3M | 0.15% |
79,907
-43,127
| -35% | -$9.48M |
|
152
CVS Health
CVS
$137B
| $21.2M | 0.15% |
306,772
-210,940
| -41% | -$15M |
|
153
Fair Isaac
FICO
$28.7B
| $21M | 0.15% |
25,968
+1,097
| +4% | +$823K |
|
154
Immunocore
IMCR
$1.78B
| $21M | 0.15% |
350,014
+32,254
| +10% | +$1.84M |
|
155
Brown & Brown
BRO
$22.9B
| $20.6M | 0.15% |
298,726
+39,306
| +15% | +$2.5M |
|
156
Guardant Health
GH
$19.5B
| $20M | 0.14% |
559,362
+38,180
| +7% | +$1.1M |
|
157
Protagonist Therapeutics
PTGX
$8.75B
| $20M | 0.14% |
725,000
+100,000
| +16% | +$2.5M |
|
158
Zebra Technologies
ZBRA
$12.4B
| $20M | 0.14% |
67,494
-2,939
| -4% | -$824K |
|
159
Applied Materials
AMAT
$426B
| $19.9M | 0.14% |
137,869
-463,287
| -77% | -$58M |
|
160
Ambarella
AMBA
$2.99B
| $19.8M | 0.14% |
236,590
| – | – |
|
161
Datadog
DDOG
$87.9B
| $19.8M | 0.14% |
201,125
-411
| -0.2% | -$34.4K |
|
162
Cerence
CRNC
$382M
| $19.6M | 0.14% |
672,092
+39,669
| +6% | +$1.09M |
|
163
Netflix
NFLX
$292B
| $19.6M | 0.14% |
445,160
-227,460
| -34% | -$8.38M |
|
164
Ameresco
AMRC
$1.15B
| $19.4M | 0.14% |
399,882
-66,229
| -14% | -$2.98M |
|
165
Exelixis
EXEL
$13.9B
| $19.1M | 0.14% |
1,001,637
-535,284
| -35% | -$10.3M |
|
166
Pinduoduo
PDD
$118B
| $19.1M | 0.14% |
276,800
-34,140
| -11% | -$2.35M |
|
167
IBM
IBM
$202B
| $18.9M | 0.14% |
141,522
-51,980
| -27% | -$6.71M |
|
168
Prologis
PLD
$138B
| $18.8M | 0.14% |
153,121
-40,103
| -21% | -$4.93M |
|
|
IMGN
169
DELISTED
Immunogen Inc
IMGN
| $18.7M | 0.14% |
992,582
-1,396,714
| -58% | -$16.5M |
|
170
Celldex Therapeutics
CLDX
$2.77B
| $18.7M | 0.14% |
550,509
-45,000
| -8% | -$1.52M |
|
171
Lamb Weston
LW
$6.82B
| $18.6M | 0.13% |
162,145
+148,590
| +1,096% | +$16.6M |
|
172
Edwards Lifesciences
EW
$47.6B
| $18.4M | 0.13% |
195,040
-68,754
| -26% | -$5.98M |
|
173
Boston Scientific
BSX
$65.8B
| $18.3M | 0.13% |
339,004
-73,721
| -18% | -$3.85M |
|
174
Graphic Packaging
GPK
$3.26B
| $18.2M | 0.13% |
758,677
+9,569
| +1% | +$240K |
|
175
eBay
EBAY
$48.6B
| $17.7M | 0.13% |
395,985
-1,611
| -0.4% | -$71.5K |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2023 Portfolio in Review
As of Q2 2023, Candriam SCA held 905 positions worth $13.8B, down 4% from $14.4B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Candriam SCA withdrew a net $2.79B in Q2 2023, closing 194 positions and reducing 448 holdings. Its most notable exit was Thomson Reuters, an estimated $19.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, up from 31% a quarter earlier, followed by Technology and Financials.
Against the trend, Candriam SCA opened a new position in Vir Biotechnology worth $8.7M.
- Candriam SCA's largest Q2 2023 buy was Vir Biotechnology: 354,645 shares worth $8.7M.
- Candriam SCA added most to Lam Research in Q2 2023, an estimated $66.4M increase.
- Candriam SCA's biggest Q2 2023 reduction was Microsoft, cutting an estimated $182M.
- Candriam SCA fully exited Thomson Reuters in Q2 2023, selling an estimated $19.8M.
- Candriam SCA's ten largest holdings make up 25% of its $13.8B portfolio in Q2 2023.
- Candriam SCA opened 29 new positions and closed 194 in Q2 2023.
- Candriam SCA's portfolio value fell 4% quarter-over-quarter to $13.8B.
Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.